Get short URL
In early October, when US President Donald Trump was diagnosed with COVID-19, he was treated with Regeneron’s antibody cocktail and praised it, pledging to fast-track an approval for the medication.
Regeneron’s polyclonal antibody cocktail, which was a part of Trump’s coronavirus treatment, received an emergency use authorization (EUA) from the US Food and Drug Administration (FDA) on Saturday.
“The FDA remains committed to advancing the nation’s public health during this unprecedented pandemic. Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” said FDA Commissioner Stephen M. Hahn.
Regeneron’s antibody cocktail contains of two monoclonal antibodies named casirivimab and imdevimab, which are “specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells”.
The EUA is, however, different to approval, as FDA warns that it only concluded that “potential benefits of these antibodies outweigh the known and potential risks”.
“There are no adequate, approved and available alternative treatments to casirivimab and imdevimab administered together for the authorized population”, FDA warned.
The antibody cocktail was a part of Trump’s anti-coronavirus therapy in early October, when he tested positive for COVID-19 and was admitted to Walter Reed military hospital. He was content with the results of his treatment, boasting his speedy recovery and praising Regeneron’s medication, noting that he would be “in much worse shape” had he not taken the antibody cocktail.
After his recovery, Trump said that he was pushing to get Regeneron’s antibody cocktail approved and out to hospitals.
DETAILS TO FOLLOW